INTENT TO SOLE SOURCE FOR SENTINEL 2.0 BRIDGE CONTRACT TO HARVARD PILGRIM HEALTH CARE INC.
FDA · FDA CENTER FOR DRUG EVALUATION AND RESEARCH
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation FDAINTENTTOSOLESOURCEBRIDGESENTINEL2 in this department, oldest first.
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
Intent to Award Sole Source Contract 1/28/2026 The Food and Drug Administration (FDA) intends to award a sole source bridge contract to Harvard Pilgrim Health Care Inc to extend Sentinel 2.0 operations. This bridge contract will provide uninterrupted service for the Sentinel system which includes the following: Active Risk Identification and Analysis System (ARIA Real World Claims (RWE)-Electronic Health Records (ERH) linked data Leadership and Program Management, Atlassian Access and Supporting Federal Information Security Modernization Act (FISMA) Compliance Period of Performance: Base Perio… (show all)
d: 3/29/2026 through 9/28/2026 (six months) Option Period 1: 9/29/2026 through 3/28/2027 (six months) Option Period 2: 3/29/2027 through 9/28/2027 (six months) Justification: Harvard Pilgrim Health Care Inc., as the incumbent contractor, possesses the necessary expertise and knowledge to ensure continuity of operations during the bridge period. This temporary measure will maintain current service levels until the competitive follow-on contract (Sentinel 3.0) is awarded. The sole source award to Harvard Pilgrim Health Care Inc. is a necessary step to prevent a lapse in critical services and to ensure that the program's momentum is maintained until a long-term, competitively awarded contract can be put in place. Program Background: The Sentinel System is a Congressionally mandated program (FDAAA 2007) that requires FDA to collaborate with public, academic, and private entities to develop methods for obtaining access to disparate data sources and to validate means of linking and analyzing safety data from multiple sources. FDA has created a national electronic Active Post-market Risk Identification and Analysis (ARIA) system with at least 100 million individuals. ARIA fulfills FDA's mandate (section 505(o)(3)(D)(i) of the Federal Food, Drug, and Cosmetic Act) to modernize safety surveillance by capitalizing on electronic healthcare data, advancing epidemiological methods, and expanding the FDA's capabilities. The Sentinel System also responded to the congressionally-mandated Real-World Evidence Medical Data Enterprise that requires a �Queryable�EHR� with at least 10 million lives. This aligns with the 21st Century Cures Act (�Cures Act�) which promotes and strengthens the use of Real-World Evidence (RWE) to support or satisfy post-approval study requirements. The Sentinel System uses RWE for this purpose and is dedicated to developing new analytical approaches and more efficient mechanisms to access data from electronic healthcare data, including electronic health records (EHRs) for at least ten million individuals. The Sentinel System delivers on these statutory requirements and helps to fulfill the Office of Surveillance and Epidemiology (OSE) mission to monitor and evaluate the safety profiles of drugs available to American consumers using a variety of tools and disciplines throughout the life cycle of the drugs. The Sentinel System portfolio of work included in this Bridge Contract supports the Tasks needed to support, monitor, and operationalize the Sentinel System as well as to support the Sentinel System�s presence in the public sphere to provide the public with transparency on Sentinel System work. Response to Notice: Be advised that the aforementioned information is anticipatory in nature and is not binding. This notice is not a request for competitive proposals; however, any firm believing that they can fulfill the requirement of providing these services may be considered by the Agency. Interested parties shall identify their interest and capabilities in response to this synopsis within 7 calendar days of publication and must clearly demonstrate their ability to successfully fulfill all the above requirements. The Government reserves the right not to respond to any expressions of interest received. Only written comments, questions, or concerns regarding this notice will be accepted. Please submit them via e-mail to Howard Yablon at howard.yablon@fda.hhs.gov within the timeframe specified in this special notice. The Government will not reimburse any submissions. All costs associated with submitting a response will be the sole responsibility of the submitting party. A determination by the Government not to compete this proposed contract action based upon responses to this notice will be made at the sole discretion of the Government. The Government will review all submitted information solely to determine whether to pursue a competitive procurement process. If the Government decides to award the proposed sole source contract, the justification and approval documentation will be posted on this website. All information received in response to this notice that is marked Proprietary will be handled accordingly. The Government shall not be liable for or suffer any consequential damages for any proprietary information not properly identified. Proprietary information will be safeguarded in accordance with the applicable Government regulations. Submissions will not be returned.
Who won similar work
9 award notices on SAM.gov in the last 24 months. Matched by: Same agency (FDA), same industry group (NAICS 541).
Single-winner award sizes (9): middle half $10.0M to $26.1M, median $15.7M; range $162K to $120.8M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| Please_See_Spreadsheet Silver Spring MD 20993 USA | 3 | $153.2M | Oct 8, 2026 |
| TRANQUIL CLINICAL AND RESEARCH CONSULTING SERVICES LLC | 1 | $50.0M | Sep 16, 2025 |
| TOXICOLOGIC PATHOLOGY ASSOCIATES INC | 1 | $26.1M | Sep 15, 2025 |
| IHRC, INCORPORATED | 1 | $14.5M | Sep 16, 2026 |
| VITALANT Scottsdale AZ 85258 USA | 1 | $10.0M | Sep 8, 2025 |
| ES SQUARED, LLC | 1 | $2.4M | Apr 13, 2026 |
| THINKTRENDS, LLC | 1 | $162K | Sep 29, 2025 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- Oct 8, 2026Please_See_Spreadsheet Silver Spring MD 20993 USA$120.8MFY26 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory ScienceNo listed company matched (Materiality N/A)
- Sep 16, 2026IHRC, INCORPORATED$14.5MFDA Occupational Safety, Industrial Hygiene, Information Systems, and Training (OSIST) IDIQNo listed company matched (Materiality N/A)
- Apr 13, 2026ES SQUARED, LLC$2.4MFDA Nationwide Ergonomic ServicesNo listed company matched (Materiality N/A)
- Jan 13, 2026Please_see_Spreadsheet Silver Spring MD 20993 USA$16.7MFY25 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory ScienceNo listed company matched (Materiality N/A)
- Jan 8, 2026Please_see_Spreadsheet Silver Spring MD 20993 USA$15.7MFY25 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory ScienceNo listed company matched (Materiality N/A)
- Sep 29, 2025THINKTRENDS, LLC$162KThinkTrends Software SupportNo listed company matched (Materiality N/A)
- Sep 16, 2025TRANQUIL CLINICAL AND RESEARCH CONSULTING SERVICES LLC$50.0MFood and Drug Administration (FDA) Office of Clinical Pharmacology (OCP) � Multi-phase/Multi- site Clinical Studies and Laboratory Support Indefinite Delivery-Indefinite Quantity (IDIQ) Type ContractNo listed company matched (Materiality N/A)
- Sep 15, 2025TOXICOLOGIC PATHOLOGY ASSOCIATES INC$26.1MFDA NCTR On-Site Pathology ServicesNo listed company matched (Materiality N/A)
- Sep 8, 2025VITALANT Scottsdale AZ 85258 USA$10.0MTransfusion-Transmissible Infections Monitoring System (TTIMS)No listed company matched (Materiality N/A)
Competitive landscape
For the 7 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Food & Drug Administration (FDA) since 2024 (0 filings)
- 0 of their lobbyists list a past Food & Drug Administration (FDA) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 129 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 0 of the past winners are listed companies
- 0 insider buys and 0 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.